Press Release ***For Immediate Release***

Granules India Ltd., Issues Voluntary Recall of one batch of Naproxen Sodium 220mg tablets

Hyderabad, 13th September, 2021: Granules India Limited, in a response towards certain media articles announced that Granules USA, Inc., a wholly-owned foreign subsidiary of the Company located in New Jersey, NY, is voluntarily recalling one batch of Naproxen Sodium 220mg tablets at a retail level due to a minor "CGMP deviation". One batch has 11.4 million units of Naproxen tablets out of which 0.9 million units that were released into the market were recalled. Financially, this does not have a material impact on the Company.

"Granules manufactured and released a batch using Active Pharmaceutical Ingredient (API) from an alternate source prior to the final approval of a filed Prior Approval Supplement. We have since received the authorization to use the API for this ANDA. There was absolutely no harm done at a patient level because the API used in the batch is from an FDA approved source." said **G. N. Prashanth, Senior Vice President & Head- Corporate Quality Assurance – Granules India Ltd.**

Granules has not received any reports of adverse event that have been confirmed to be directly related to this recall as of the date.

END

About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best in class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 75+ countries with offices across India, U.S. and U.K. The Company has 7 manufacturing facilities out of which 6 are located in India and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.

Safe Harbor: This document is to provide the general background information about the Company's activities as at the date of the release. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein. This release may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates or employees have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein. No part of this release may be reproduced, quoted or circulated without prior written approval from Granules India Limited.

Investor Contacts:

Krishna Raghunathan Vice President – Finance and Investor Relations 040-69043573 krishna.raghunathan@granulesindia.com	**Chaitanya Tummala** Company Secretary 040-69043614 chaitanya.tummala@granulesindia.com